Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Tim Opler, a managing director at Stifel, has even suggested that ponsegromab could become a “monster” drug, with potential ...

The potential for ponsegromab to become a blockbuster drug exists, but the uncertainties surrounding the trial timeline and strategic execution contribute to maintaining a Hold rating on Pfizer ...

Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower cholesterol, resulting in buyers paying ...

Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend ...

On behalf of the Pfizer team, thank you for joining us ... We had a Phase II readout of ponsegromab, which is another in-house discovered and developed by us. We are encouraged by the potential ...

The third-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www.pfizer.com.

NEW YORK, Oct 15 (Reuters) - Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as it faces pressure from activist hedge fund ...

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide.

Third-Quarter 2024 Reported (4) Diluted EPS of $0.78 and Adjusted (2) Diluted EPS of $1.06 On Track to Deliver Net Cost Savings of At Least $5.5 Billion from Previously Announced Cost Reduction ...